ALLR Stock Overview
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Allarity Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$2,520.00 |
| 52 Week Low | US$2.01 |
| Beta | 0.24 |
| 1 Month Change | -69.74% |
| 3 Month Change | -78.35% |
| 1 Year Change | -99.78% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| ALLR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -51.2% | -2.8% | -1.7% |
| 1Y | -99.8% | -0.2% | 22.4% |
Return vs Industry: ALLR underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: ALLR underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| ALLR volatility | |
|---|---|
| ALLR Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ALLR's share price has been volatile over the past 3 months.
Volatility Over Time: ALLR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 6 | Thomas Jensen | www.allarity.com |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty.
Allarity Therapeutics, Inc. Fundamentals Summary
| ALLR fundamental statistics | |
|---|---|
| Market cap | US$648.78k |
| Earnings (TTM) | -US$20.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ALLR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALLR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.42m |
| Earnings | -US$20.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -66.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -47.3% |
How did ALLR perform over the long term?
See historical performance and comparison